Prevention of infections associated with vascular catheters

International Journal of Artificial Organs

Volumn 31, Issue 9, 2008, Pages 810-819

  Darouiche, Rabih O ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Anti infective approach; Catheter colonization; Catheter infection; Prevention

Indexed keywords

% REDUCTIONS; ANTI-INFECTIVE APPROACH; ANTI-INFECTIVES; CATHETER COLONIZATION; CATHETER INFECTION; CLINICAL INFECTION; COLONISATION; EDUCATIONAL PROGRAM; INFECTION CONTROL; PREVENTION;

CATHETERS;

ALCOHOL; AMINOGLYCOSIDE ANTIBIOTIC AGENT; BENZALKONIUM CHLORIDE; CEFAZOLIN; CEPHALOSPORIN DERIVATIVE; CHLORHEXIDINE; CIPROFLOXACIN; HEPARIN; MINOCYCLINE; PLATINUM; POLYPEPTIDE ANTIBIOTIC AGENT; POLYURETHAN; POVIDONE IODINE; RIFAMPICIN; SILICONE; SILVER; SULFADIAZINE SILVER; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTISEPSIS; ARTICLE; BACTERIAL COLONIZATION; BACTERIUM CONTAMINATION; CANDIDA; CATHETER INFECTION; CATHETER THROMBOSIS; CENTRAL VENOUS CATHETER; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST CONTROL; DRUG EFFICACY; GRAM NEGATIVE BACTERIUM; HEALTH CARE COST; HUMAN; INCIDENCE; INDWELLING CATHETER; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RATE; INTRAVASCULAR CATHETER; MONOTHERAPY; NONHUMAN; PATHOGENESIS; PRACTICE GUIDELINE; PROTECTION; SKIN DECONTAMINATION; STAPHYLOCOCCUS;

EID: 56349103147     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880803100909     Document Type: Article

References (68)

1. Demetriades D, May A, Gamble H. When does a Centers for Disease Control and Prevention recommendation become standard of care? Perhaps in the courtroom. American College of Surgeons mock trial: line sepsis liability. J Am Coll Surg 2008; 206: 370-5.
2. McGee D, Gould M. Preventing complications of central venous catheterization. N Engl J Med 2003; 348: 1123-33.
3. Maki DG, Ringer M, Alvarado CJ. Prospective randomized trial of povidone-iodine, alcohol, and chlorhexidine for prevention of Infection associated with central venous and arterial catheters. Lancet 1991; 338: 339-43.
4. Darouiche RO, Berger DH, Khardori N, et al. Comparison of antimicrobial impregnation with tunneling of longterm central venous catheters: A randomized, controlled trial. Ann Surg 2005; 242: 193-200.
5. Mermel LA. Prevention of intravascular catheter-related infections. Ann Intern Med 2000; 132: 391-402.
6. Warren DK, Quadir WW, Hollenbeak CS, et al. Attributable cost of catheter-associated bloodstream infections among intensive care patients in a nonteaching hospital. Crit Care Med 2006; 34: 2084-9.
7. Pittet D, Tarara D, Wenzel RP. Nosocomial bloodstream infection in critically ill patients: excess length of stay, extra costs, and attributable mortality. JAMA 1994; 271: 1598-601.
8. Heiselman D. Nosocomial bloodstream infections in the critically ill (Letter). JAMA 1994; 272: 1819-20.
9. Pittet D, Wenzel RP. Nosocomial bloodstream infections in the critically ill (Letter). JAMA 1994; 272: 1820-1.
10. Dimick JB, Pelz RK, Consunji, et al. Increased resource use associated with catheter-related bloodstream infection in the surgical intensive care unit. Arch Surg 2001; 136: 229-34.
11. Sieradzki K, Roberts RB, Haber SW, Tomasz A. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N Engl J Med 1999; 340: 517-23.
12. Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 1999; 340: 493-501.
13. Maki DG, Cobb L, Garman JK, et al. An attachable silver-impregnated cuff for prevention of infection with central venous catheters: a prospective randomized multicenter trial. Am J Med 1988; 85: 307-14.
14. Salzman MB, Isenberg HD, Shapiro JF, et al. A prospective study of the catheter hub as the portal of entry for organisms causing catheter-related sepsis in neonates. J Infect Dis 1993; 167: 487-90.
15. Raad II, Bodey GP. Infectious complications of indwelling vascular catheters. Clin Infect Dis 1992; 15: 197-208.
16. Darouiche RO. Device-associated infections: a macro-problem that starts with microadherence. Clin Infect Dis 2001; 33: 1567-72.
17. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science 1999; 284: 1318-22.
18. Darouiche RO, Dhir A, Miller AJ, Landon GC, Raad II, Musher DM. Vancomycin penetration into biofilm covering infected prostheses and effect on bacteria. J Infect Dis 1994; 170: 720-3.
19. Kumon H, Tomochika K, Matunaga T, et al. A sandwich cup method for the penetration assay of antimicrobial agents through Pseudomonas exopolysaccharides. Microbiol Immunol 1994; 38: 615-9.
20. Jansen B, Rinck M, Wolbring P, Strohmeier A, Jahns T. In vitro evaluation of the antimicrobial efficacy and biocompatibility of a silver-coated central venous catheter. J Biomater Appl 1994; 9: 55-70.
21. Kampf G, Dietze B, Grobe-Siestrup C, Wendt C, Martiny H. Microbicidal activity of a new silver-containing polymer, SPI-ARGENT II. Antimicrob Agents Chemother 1998; 42: 2440-2.
22. Gilbert JA, Cooper RC, Puryear HA, et al. A swine model for the evaluation of efficacy of anti-microbial catheter coatings. J Biomater Sci Polym Ed 1998; 9: 931-42.
23. Goldschmidt H, hahn U, Satwender HJ, et al. Prevention of catheter-related infections by silver-coated central venous catheters in oncological patients. Zentralbl Bakteriol 1995; 283: 215-23.
24. Bach A, Eberhardt H, Frick A, et al. Efficacy of silvercoating central venous catheters in reducing bacterial colonization. Crit Care Med 1999; 27: 515-21.
25. Dunser MW, Mayr AJ, Hinterberger G, et al. Central venous catheter colonization in critically ill patients: a prospective, randomized, controlled study comparing standard with two antiseptic-impregnated catheters. Anesth Analg 2005; 101: 1778-84.
26. Kalfon P, de Vaumus C, Samba D, et al. Comparison of silver-impregnated with standard multi-lumen central venous catheters in critically ill patients. Crit Care Med 2007; 35: 1032-9.
27. Trerotola S, Johnson M, Shah H, et al. Tunneled hemodialysis catheters: use of a silver-coated catheter for prevention of infection-a randomized study. Radiology 1998; 207: 491-6.
28. Darouiche RO. Anti-infective efficacy of silver-coated medical prostheses. Clin Infect Dis 1999; 29: 1371-7.
29. Mermel LA, Stolz SM, Maki DG. Surface antimicrobial activity of heparin-bonded and antiseptic-impregnated vascular catheters. J Infect Dis 1993; 167: 920-4.
30. Moss HA, Tebbs Se, Faroqui MH, et al. A central venous catheter coated with benzalkonium chloride for the prevention of catheter-related microbial colonization. Eur J Anesthesiol 2000; 17: 680-7.
31. Jaeger K, Osthaus A, Heine J, et al. Efficacy of a benzalkonium chloride-impregnated central venous catheter to prevent catheter-associated infection in cancer patients. Eur J Chemother 2001; 47: 50-55.
32. Kamal GD, Pfaller MA, Rempe LE, et al. Reduced intravascular catheter infection by antibiotic bonding. JAMA 1991; 265: 2364-8.
33. Thornton J, Todd NJ, Webster NR. Central venous line sepsis in the intensive care unit: a study comparing antibiotic coated catheters with, plain catheters. Anesthesia 1996; 51: 1018-20.
34. Ranucci M, Isgro G, Giomarelli PP, et al. Impact of oligon central venous catheters on catheter colonization and catheter-related bloodstream infection. Crit Care Med 2003; 31: 52-9.
35. O'Grady NP, Alexander M, Dellinger EP, et al. Guidelines for the prevention of intravascular catheter-related infections. Centers for Disease Control and Prevention. MMWR Morb Mortal Wkly Rep 2002; 51: 1-29.
36. Chaivakunapruk N, Veenstra N, Lipsky BA, et al. Chlorhexidine compared with povidone-iodine solution for vascular catheter-site care: a meta-analysis. Ann Intern Med 2002; 136: 792-801.
37. Raad II, Hohn DC, Gilbreath BJ, et al. Prevention of central venous catheter-related infections by using maximal sterile barrier precautions during insertion. Infect Control Hosp Epidemiol 1994; 15: 231-8.
38. Maki DG, Stolz SM, Wheeler S, et al. Prevention of central venous catheter-related bloodstream infection by use of an antiseptic-impregnated catheter: a randomized, controlled study. Ann Intern Med 1997; 127; 257-66.
39. Tennenberg S, Lieser M, McCurdy B, et al. A prospective randomized clinical trial of an antibiotic - and antiseptic-coated central venous catheter in the prevention of catheter-related infections. Arch Surg 1997; 132: 1348-51.
40. Heard SO, Wagle M, Vijayakumar E, et al. The influence of triple-lumen central venous catheters coated with chlorhexidine/silversulfadiazine on the incidence of catheter-related bacteremia: a randomized, controlled clinical trial. Arch Intern Med 1998; 158; 81-7.
41. Rupp ME, Lisco SJ, Lipsett PA, et al. Effect of a second-generation venous catheter impregnated with chlorhexidine and silver sulfadiazine on central catheter-related infections: a randomized, controlled trial. Ann intern Med 2005; 143: 570-80.
42. Veenstra DL, Saint S, Saha S, Lumley T, Sullivan SD. Efficacy of antiseptic-impregnated central venous catheters in preventing catheter-related bloodstream infection. JAMA 1999; 281: 261-7.
43. Bassetti S, Hu J, D'Agastino, Jr, et al. Prolonged antimicrobial activity of a catheter containing chlorhexidine-silver sulfadiazine extends protection against catheter infection. Antimicrob Agents Chemother 2001; 45: 1535-8.
44. Logghe C, Van Ossel C, D'Hoore W, et al. Evaluation of chlorhexidine and silver-sulfadiazine impregnated central venous catheters for the prevention of bloodstream infection in leukemic patients: a randomized controlled trial. J Hosp Infect 1997; 37: 145-56.
45. Darouiche RO, Raad II, Bodey GP, et al. Antibiotic susceptibility of staphylococcal isolates from patients with vascular catheter-related bacteremia: potential role of the combination of minocycline and rifampin. Int J Antimicrob Agents 1995; 6: 31-6.
46. Raad I, Darouiche R, Hachem R, et al. The broad spectrum activity and efficacy of catheters coated with minocycline and rifampin. J Infect Dis 1996; 173: 418-24.
47. Raad I, Hanna H, Jiang Y, et al. Comparative activities of daptomycin, linezolid, and tigecycline against catheterrelated methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm. Antimicrob Agents Chemother 2007; 51: 1656-60.
48. Widmer AF, Frei R, Rajacic Z, et al. Correlation between in vivo and in vitro efficacy of antimicrobial agents against foreign body infections. J Infect Dis 1990; 162: 96-102.
49. Raad I, Darouiche R, Dupuis J, et al. Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and bloodstream infections: a randomized, double-blind trial. Ann Intern Med 1997; 127: 267-74.
50. Darouiche RO, Raad II, Heard SO, et al. A comparison of two antimicrobial-impregnated central venous catheters. N Engl J Med 1999; 340: 1-8.
51. Marick PE, Abraham G, Carean P, et al. The ex vivo antibacterial activity and colonization rate of two antimicrobial-coated central venous catheters. Crit Care Med 1999; 27: 1128-31.
52. Bassetti S, Hu J, D'Agastiono, et al. In vitro zones of inhibition of coated vascular catheters predict efficacy in preventing catheter infection with Staphylococcus aureus in vivo. Eur J Clin Microbiol Infect Dis 2000; 19: 612-7.
53. Hanna H, Benjamin R, Chatzinikolau I, et al. Long-term silicone central venous catheters impregnated with minocycline and rifampin decrease rates of catheter-related bloodstream infection in cancer patients: a prospective, randomized clinical trial. J Clin Oncol 2004; 22: 3163-71.
54. Chatzinikolaou I, Hanna H, Graviss L, et al. Clinical experience with minocycline and rifampin-impregnated central venous catheters in bone marrow transplantation recipients: efficacy and low risk of developing staphylococcal resistance. Infect Control Hosp Epidemiol 2003; 24: 961-3.
55. Crnich CJ, Maki DG. The promise of novel technology for the prevention of intravascular device-related bloodstream infection. I. Pathogenesis and short-term devices. Clin Infect Dis 2002; 34: 1232-42.
56. Crnich CJ, Maki DG. The promise of novel technology for the prevention of intravascular device-related bloodstream infection. II. Long-term devices. Clin Infect Dis 2002; 340: 1362-8.
57. Veenstra DL, Saint S, Sullivan SD. Cost-effectiveness of antiseptic-impregnated central venous catheters for the prevention of catheter-related bloodstream infection. JAMA 1999; 282: 554-60.
58. Shorr AF, Humphreys CW, Helman DL. New choices for central venous catheters: potential financial implications. Chest 2003; 124: 275-84.
59. Schwartz C, Henrickson KJ, Roghmann K, et al. Prevention of bacteremia attributed to luminal colonization of tunneled central venous catheters with vancomycin-susceptible organisms. J Clin Oncol 1990; 8: 591-7.
60. Carratala J, Njubo J, Fernandez-Sevilla A, et al. Randomized, double-blind trial of an antibiotic-lock technique for prevention of gram-positive central venous catheterrelated infection in neutropenic patients with cancer. Antimicrob Agents Chemother 1999; 43: 2200-4.
61. Henrickson KJ, Axtell RA, Hoover SM, et al. Prevention of central venous catheter-related infections and thrombotic events in immunocompromised children by the use of vancomycin/ciprofloxacin/heparin flush solution: A randomized, multicenter, double-blind trial. J Clin Oncol 2000; 18: 1269-78.
62. Rackoff WR, Weiman M, Jakobowski D, et al. A randomized, controlled trial of the efficacy of a heparin and vancomycin solution in preventing central venous catheter infections in children. J Pediatr 1995; 127: 147-51.
63. Safdar N, Maki DG. Use of vancomycin-containing lock or flush solutions for prevention of bloodstream infection associated with central venous access devices: a meta-analysis of prospective, randomized trials. Clin Infect Dis 2006; 43: 474-84.
64. Segura M, Alvarez-Lerma F, Tellado JM, et al. Advances in surgical technique: a clinical trial on the prevention of catheter-related sepsis using a new hub model. Ann Surg 1996; 223: 363-9.
65. Luna J, Masdeu G, Perez M, et al. Clinical trial evaluating a new hub device designed to prevent catheter-related sepsis. Eur J Clin Microbiol Infect Dis 2000; 19: 655-62.
66. Warren DK, Zack JE, Mayfield JL, et al. The effect of an education program on the incidence of central venous catheter-associated bloodstream infection in a medical ICU. Chest 2004; 126: 1612-8.
67. Sherertz RJ, Ely EW, Westbrook DM, et al. Education of physicians-in-training can decrease the risk for vascular catheter infection. Ann Intern Med 2000; 132: 641-8.
68. Bijma R, Girbes AR, Klejer DJ, et al. Preventing central venous catheter-related infection in a surgical intensive-care unit. Infect Control Hosp Epidemiol 1999; 20: 618-20.